264 related articles for article (PubMed ID: 24458248)
1. Genetic alterations in chondrosarcomas - keys to targeted therapies?
Samuel AM; Costa J; Lindskog DM
Cell Oncol (Dordr); 2014 Apr; 37(2):95-105. PubMed ID: 24458248
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.
Bovée JV; van den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
Lab Invest; 2000 Dec; 80(12):1925-34. PubMed ID: 11140704
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
4. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
5. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
[TBL] [Abstract][Full Text] [Related]
6. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT.
de Andrea CE; Reijnders CM; Kroon HM; de Jong D; Hogendoorn PC; Szuhai K; Bovée JV
Oncogene; 2012 Mar; 31(9):1095-104. PubMed ID: 21804604
[TBL] [Abstract][Full Text] [Related]
7. Novel strategies for the treatment of chondrosarcomas: targeting integrins.
Chen JC; Fong YC; Tang CH
Biomed Res Int; 2013; 2013():396839. PubMed ID: 24490159
[TBL] [Abstract][Full Text] [Related]
8. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.
Schrage YM; Hameetman L; Szuhai K; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
Am J Pathol; 2009 Mar; 174(3):979-88. PubMed ID: 19179614
[TBL] [Abstract][Full Text] [Related]
9. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
10. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.
Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC
Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
13. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
[TBL] [Abstract][Full Text] [Related]
14. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
de Andrea CE; San-Julian M; Bovée JVMG
Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
[TBL] [Abstract][Full Text] [Related]
15. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
17. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
[TBL] [Abstract][Full Text] [Related]
18. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Cleton-Jansen AM; van Beerendonk HM; Baelde HJ; Bovée JV; Karperien M; Hogendoorn PC
Clin Cancer Res; 2005 Nov; 11(22):8028-35. PubMed ID: 16299232
[TBL] [Abstract][Full Text] [Related]
19. Lack of Bcl10 mutations in malignant cartilaginous tumors.
Park YK; Park HR; Kim YW; Chi SG; Unni KK
Int J Mol Med; 2002 Mar; 9(3):217-9. PubMed ID: 11836626
[TBL] [Abstract][Full Text] [Related]
20. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.
Totoki Y; Yoshida A; Hosoda F; Nakamura H; Hama N; Ogura K; Yoshida A; Fujiwara T; Arai Y; Toguchida J; Tsuda H; Miyano S; Kawai A; Shibata T
Genome Res; 2014 Sep; 24(9):1411-20. PubMed ID: 25024164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]